Targetted medicine to reduce melanoma mutational burden
22 Sep 2016
Targetted medicine to reduce melanoma mutational burden
VISMO trial to treat basal cell carcinoma
Checkpoint inhibitor therapy for treating melanoma
Metabolomics: Reversing drug resistance
Tumour heterogeneity and the impact on patient care
Developing new models in SCLC
Future of imaging in lung cancer
Understanding the mechanisms of immunotherapy in lung cancer
Nitroglycerin in cancer treatment
PDL1 and other biomarkers for selecting patients for immune checkpoint therapies
State of the art imaging and lung cancer management
Future smart surgical approaches for brain metastases